I'm exploring a startup idea around in-space manufacturing (ISM) in low Earth orbit using automated, modular payloads (free-flyers or commercial stations like Starlab/Axiom). The core thesis is leveraging microgravity to produce materials that are meaningfully superior to Earth-made versions in small-but-high-value batches (no need for mass production in orbit).

Three specific product swimlanes that are viable (all hybrid model: grow superior version in space → return to Earth → use/expand on Earth):

1. Pharma/biotech crystals: Novel polymorphs or ultra-pure API crystals (e.g., for monoclonal antibodies, small molecules) with better solubility, stability, bioavailability, or controlled release. Think reformulating IV drugs into injectables or enabling new patents on blockbusters.

2. Semiconductor seeds: Ultra-pure wide/ultra-wide bandgap crystal seeds (GaN, SiC, AlN, etc.) grown defect-free in microgravity. These propagate into larger terrestrial boules with dramatically lower dislocations/impurities → better power electronics, RF devices, radiation-hardened chips for AI, defense, EVs, 5G/6G.

3. Regenerative medicine constructs: Vascularized thick tissues, artificial retinas (protein-based), or patient-derived organoids (brain, heart, liver) that self-assemble better in microgravity (no gravitational collapse/sagging). End uses: therapeutic implants (e.g., for blindness, organ failure bridges), or premium 3D disease models for faster/more accurate drug screening.

Questions for HN (especially if you're in pharma R&D, semiconductor materials, defense electronics, regenerative biotech, or related fields):

>> Would your organization pay a meaningful premium (e.g., 5–50× terrestrial equivalents per gram/kg, or royalties/licensing) for access to these space-made materials/constructs once qualified?

>> What specific pain points (yield, defects, vascularization failure, formulation limits, supply-chain risks) would make this worth pursuing vs. sticking to Earth methods?

>> Which of the three lanes feels most compelling / urgent to you right now, and why? (Or is there a fourth lane I'm missing?)

>> Rough ballpark: What volume/pricing would make it interesting for early adoption (e.g., qualification batches, pilot programs)?

>> Any obvious showstoppers (regulatory, reentry survival, cost, timeline) that kill the idea?

I'm not selling anything yet, just trying to validate whether there's real demand before sinking more time/money. Background: idea stems from following Varda, Redwire, United Semiconductors, LambdaVision, NASA InSPA awards, etc.

Thanks for any candid thoughts — technical skepticism, customer perspectives, or "this is nonsense because X" all welcome.

(If you're in one of these spaces and open to a quick DM/chat, even better.)

Thanks!

Talent is a loop, not a gift

RPPG-Enabled Contactless Pulse Rate Monitoring Software in CVD Patients

Codex 101 Guide from a Recovering PM

Paying without Google: New consortium wants to remove custom ROM hurdles

Xygeni/xygeni-action GitHub Action is compromised – poisoned tag is still live

New AI Note Tool

Shipping Grayscale Photos at Small Scale

Head to head: Claude Code (Opus 4.6 / 1M) vs. Cursor (Composer 1.5 / 200k)

Managing My Open Source Repos with Autonomous AI Agents

Aatel: The Anti-AI Training Ethical License – What It Is and Why It Was Built

Cinder CSI vs. Ceph RBD CSI in Kubernetes

Sorca – Voice-first AI therapy companion

Context plane for AI agents (Rust, S3)

Music Programming Studio

Ask HN: Value and demand for space-manufactured products?

Anthropic says Trump ban puts federal contractor partnerships 'in jeopardy'

Treat Agent Output Like Compiler Output

New HIV cure approach forces hidden virus into tripping immune sensor

LibreOffice learns to speak Markdown in version 26.2

EV charger biz ELECQ zapped by ransomware crooks, customer contact data stolen

Moody humans should let AI handle bad public feedback first, study finds

Number Stations

Microsoft 365 confirms new premium tier, stuffed with AI and few discounts

Ending rent seeking in academic publishing

OpenLDAP 2.6.13 Now Available

If You're Going to Defend AI, You Should Be Honest About Its Actual Harms

Show HN: An open-source DAW plugin built on JUCE, React, and Lyria RealTime

Show HN: Dark Hacker News

The Safe Act Is an Imperfect Vehicle for Real Section 702 Reform

Claude Code, Claude Cowork and Codex #5

Show HN: A tool that automatically installs Python and common dev libraries